about
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancerTissue repair and stem cell renewal in carcinogenesisGene expression pathways of high grade localized prostate cancer.Identification of ALK gene alterations in urothelial carcinoma.Urothelial carcinoma: stem cells on the edge.Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.PI3K/mTOR signaling regulates prostatic branching morphogenesisIdentification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaHER2 as a target in invasive urothelial carcinoma.Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genesPreparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.Wnt signaling though beta-catenin is required for prostate lineage specificationReliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate CancerAndrogen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.When is prostate cancer really cancer?Tumorigenic potential of circulating prostate tumor cells.The molecular genetics of steroid 5 alpha-reductases.Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study.Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study.Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer.Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.Response to editorial comments to Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based studyProcesses of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancerCurative therapy for bladder cancer in routine clinical practice: a population-based outcomes studyMolecular profiling in muscle-invasive bladder cancer: more than the sum of its partsErratum: Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder CancerReliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsiesA three-gene DNA methylation biomarker accurately classifies early stage prostate cancerDevelopment and initial clinical correlation of a DNA methylation-based blood test for prostate cancer
P50
Q24300152-4FCD6AB8-F72F-44A1-9078-BE3162457EA9Q28294006-22267BCD-6807-47B7-88FC-07ED1CD4B1E9Q33832517-512C8FDD-7196-4705-AE24-9EEA0E94DCB8Q33989002-1C0B556D-545C-4726-A2CA-9A335FB46364Q34092411-3A60C964-7B52-4C3A-903E-21307BBB9AAEQ34698294-E94E342F-7155-4A17-87E3-2615EEC50663Q35575601-405B5567-5C0E-47CB-9E17-ECFB46E9131EQ35678391-CF8860BA-96DE-4950-8D55-A2DC7639B713Q35731224-A703C61A-3384-4D5A-A88C-8E74ECF2AA8DQ35755382-D101E307-B658-4721-B701-9AD5B9A311DDQ35866471-E0D8C702-2A78-4DCD-8088-1A9E3DD70D2FQ36010440-254C8553-E970-41F8-956C-C07DFF0835FBQ36119886-0FD0D805-32EF-4A74-A923-2115C1FBE27AQ36236135-9E224046-8F40-4EE5-97CC-8E3961393E42Q36320529-74B11C02-2277-47A8-946C-1841E49199B4Q36412510-F5E3B883-BAAF-44E9-BD8A-4C2B06237AA7Q36471474-12E29882-E053-4D06-A896-90DCD9C0BB25Q37178620-12C4ED40-79C2-4D2C-931A-D4E41D3937A5Q38203988-4C2002D5-5902-4ECE-BD5B-6FA9CFC98284Q39175526-3AE9EA6E-7068-4C56-B963-556CAFC65605Q40734799-0C1DCB8C-A8EE-406F-90C2-E3666136BF56Q41560984-DAB56FAA-2684-49FA-8DE1-D3D7E93CC6FDQ42754619-E3A62356-E3A8-4FDA-9440-C5FF45A7F1C7Q43557462-2AB40CFF-8AEC-4B70-9B3B-D6521BDAD0CAQ44883575-459215E3-F73B-43F9-9B5D-AB13A8275E06Q53596875-9DED73BA-4E56-4BBF-88AE-D1964FA8507DQ85856194-2BC26CBF-E6EC-4F69-BF9C-EB9575C51145Q86098826-A3CA590D-5309-4E70-81CE-D8EFF57E110AQ88130966-7AD91D95-6053-4594-BEC1-85CC4F288F67Q90859895-622D19B5-60AD-45F5-955A-13FECFD5E7CCQ92074380-A420B4F7-5158-4B39-8081-BA6ECF543B15Q92502617-9F5127EF-809D-4C3F-B9B3-AC284133B6C6Q92748081-0BD1A023-1E95-498F-8F6C-A24E81C0059CQ96163219-2F189939-A34E-4B9A-99C6-9E717CE121F0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Berman
@ast
David Berman
@en
David Berman
@es
David Berman
@nl
David Berman
@sl
type
label
David Berman
@ast
David Berman
@en
David Berman
@es
David Berman
@nl
David Berman
@sl
prefLabel
David Berman
@ast
David Berman
@en
David Berman
@es
David Berman
@nl
David Berman
@sl
P106
P21
P31
P496
0000-0001-5985-3698